BeiGene Shares Climb Pre-Bell After FDA Gives Favorable Opinion on Class of Cancer Treatments

MT Newswires Live09-27

BeiGene (BGNE) shares were up 3.5% in Friday's premarket activity after it said that the US Food and Drug Administration's Oncologic Drugs Advisory Committee had recognized the "favorable benefit-risk profile" of PD-1 inhibitors such as the company's Tevimbra as a first-line treatment for patients with locally advanced inoperable or metastatic esophageal squamous cell carcinoma.

The conclusion by the advisory applied to esophageal squamous cell carcinoma expressing certain specific cancer markers, the company said. It was based on several studies of PD-1 inhibitors, including Tevimbra, also called tislelizumab-jsgr.

The company said the Biologics License Applications for Tevimbra remain under FDA review. The drug has already been approved in the US for the treatment of adults with unresectable or metastatic ESCC after prior chemotherapy treatments.

Price: 220.01, Change: +7.48, Percent Change: +3.52

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment